Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CK Life Sciences International (Holdings), Inc. ( (HK:0775) ) just unveiled an update.
CK Life Sciences International (Holdings) Inc. has formed Sequencio Therapeutics Company Limited as a wholly owned subsidiary to consolidate and drive its therapeutic cancer vaccine research and development efforts. The move underscores the group’s ambition to strengthen its position in cancer immunotherapy by advancing an in-house and partnership-driven pipeline.
Sequencio will focus on developing therapeutic cancer vaccines that train patients’ immune systems to achieve durable, long-term remission with a favorable safety profile, addressing limitations of current standard-of-care treatments. Its preclinical portfolio includes a TROP2-targeting vaccine that has shown robust T-cell responses and complete tumor growth inhibition in breast and colorectal cancer mouse models, as well as candidates against PRAME, PD-L1, B7-H3 and Claudin 6.
The new unit complements CK Life Sciences’ recent strategic transactions, including gaining a majority stake in pain and neuropathy specialist Dogwood Therapeutics and exchanging its late-stage melanoma vaccine seviprotimut-L for an equity stake in TransCode Therapeutics. Together, Sequencio, TransCode and Dogwood provide the company with a broader, more diversified pipeline spanning early to late-stage projects, potentially enhancing its competitive standing and value proposition for stakeholders.
The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.
More about CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings) Inc. is a biotechnology company focused on life science research and development, with an emphasis on cancer immunotherapy and therapeutic vaccines. Through wholly owned and strategic subsidiaries, it is building a diversified R&D platform that targets substantial unmet medical needs in oncology and related therapeutic areas.
Average Trading Volume: 7,434,362
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.4B
For an in-depth examination of 0775 stock, go to TipRanks’ Overview page.